KLOW is a laboratory blend of four well-characterised research peptides — GHK-Cu, BPC-157, TB-500 (thymosin β4) and KPV. This review asks a narrow question: what does the primary literature actually report about these molecules in angiogenesis and tissue-repair models, and where does that evidence stop?

What the KLOW blend contains

KLOW is an acronym-style label for a four-peptide research mixture. Each constituent is a distinct molecule with its own literature, so any discussion of KLOW is really a discussion of four separate research programmes considered side by side:

• GHK-Cu — glycyl-L-histidyl-L-lysine complexed with copper(II). It occurs naturally in human plasma and declines with age, and has been characterised as a modulator of collagen and glycosaminoglycan turnover in skin models.²
• BPC-157 — a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a fragment of a gastric protein, studied predominantly in rodent gastrointestinal and soft-tissue models.⁹
• TB-500 — the research designation commonly applied to thymosin β4, a 43-amino-acid actin-sequestering peptide released by platelets and other cells after injury.⁵
• KPV — the C-terminal tripeptide (Lys-Pro-Val) of α-melanocyte-stimulating hormone, investigated as an anti-inflammatory signal.¹³

Two of these are available individually at Qovigen for researchers who prefer to isolate a single variable — GHK-Cu and TB-500 — which matters because the published mechanisms below were established for the isolated compounds, not for the blend. There is no peer-reviewed pharmacology describing how the four behave together, an important caveat carried through the rest of this article.

How the components influence angiogenesis at the molecular level

Angiogenesis — the sprouting of new capillaries from existing vessels — is a coordinated sequence: endothelial cells are activated, they degrade the surrounding matrix, migrate, and organise into tubes. The KLOW components have each been reported to intersect this sequence at different points, which is why they are sometimes grouped together in an experimental context.

The framing peptide for this literature is unrelated: elastin-derived peptides were shown to accelerate angiogenesis in the chick chorioallantoic membrane and to drive endothelial migration and tubulogenesis through up-regulation of the membrane protease MT1-MMP, with the effect abolished by MT1-MMP silencing.¹ That study established a general principle — short peptides can steer endothelial behaviour through matrix-remodelling enzymes — that recurs across the KLOW components.

GHK-Cu and VEGF signalling

In a 2023 wound-healing study, copper-complexed GHK delivered from a hyaluronic-acid hydrogel was reported to improve angiogenesis through vascular endothelial growth factor (VEGF) activation, alongside increased collagen remodelling and denser fibroblast populations in the treated dermis.³ The broader GHK literature frames the peptide as capable of up- and down-regulating thousands of human genes and of attracting immune and endothelial cells to a site of injury.²

TB-500 (thymosin β4) and endothelial migration

Thymosin β4 was shown decades ago to act as a chemoattractant for human umbilical vein endothelial cells, accelerating their migration into a scratch-wound and increasing matrix-metalloproteinase production — direct evidence that it promotes the migratory step of angiogenesis.⁴ Its principal biochemical property is actin sequestration, which governs the cytoskeletal remodelling that underlies cell motility.⁸ In a rat myocardial-infarction model, sustained release of thymosin β4 was associated with enhanced angiogenesis and lymphangiogenesis in infarcted tissue.⁶ Independent single-cell work identified thymosin β4 (TMSB4) as a paracrine factor released by stressed cardiomyocytes that stimulates angiogenesis by enhancing endothelial-cell migration.⁷

BPC-157 and the nitric-oxide system

Reviews of BPC-157 describe an angiogenic profile linked to the nitric-oxide (NO) system, reporting endothelial protection and vessel formation in impaired conditions, together with modulation of early-growth-response-1 (EGR-1) signalling relevant to growth-factor and matrix generation.⁹¹⁰ A dedicated review positioned BPC-157 alongside the standard angiogenic growth factors (VEGF, FGF, EGF), arguing that a single peptide reproduced angiogenic readouts across gastrointestinal, tendon, ligament, muscle and bone models.¹¹ It is worth stressing that this is a rodent and review literature, much of it from a single research group.

Cellular pathways studied in tissue repair

Beyond new vessels, tissue repair in these models involves matrix-producing fibroblasts, the mobilisation of progenitor cells, and control of the inflammatory phase. The KLOW components have been mapped onto each of these stages in separate studies.

Fibroblast activity and matrix remodelling

GHK-Cu is the most direct example: it has been reported to stimulate synthesis and breakdown of collagen and glycosaminoglycans, to modulate metalloproteinases and their inhibitors, and to restore replicative capacity to fibroblasts after radiation exposure.² In the hydrogel study, GHK-loaded matrices were associated with denser, more organised dermal collagen and higher fibroblast density in a rodent wound.³ This dual synthesis-and-remodelling behaviour is why GHK is often described as a matrix modulator rather than a simple growth stimulant.

Progenitor-cell mobilisation

Thymosin β4 is characterised as a regenerative peptide that promotes the mobilisation, migration and differentiation of stem and progenitor cells, and that decreases myofibroblast numbers in wounds — a change linked in those reviews to reduced scarring and fibrosis.⁵ In the cardiac self-assembling-peptide model, released thymosin β4 activated epicardium-derived cells and promoted their differentiation toward cardiovascular lineages.⁶

Structural readouts

BPC-157 studies report accelerated healing of tendon, ligament, muscle and bone alongside gastrointestinal endpoints, with the same dosing regimens reproducing effects across tissue types.¹¹ Researchers combining connective-tissue peptides sometimes pair BPC-157 with TB-500; Qovigen offers a fixed BPC-157 + TB-500 blend for that experimental design, although, again, the co-formulation has not itself been studied in the peer-reviewed record.

The anti-inflammatory axis: KPV and GHK

Repair is inseparable from inflammation control, and KPV is the component most clearly tied to that axis. As the C-terminal fragment of α-MSH, KPV has been reported to attenuate inflammatory responses in colonic cells and, in murine colitis models, to lower myeloperoxidase activity and down-regulate TNF-α, with recovery observed even in animals lacking a functional melanocortin-1 receptor — implying part of its action is receptor-independent.¹³ A later delivery study using hyaluronic-acid nanoparticles reported that targeted KPV both reduced inflammation and accelerated mucosal repair in a colitis model, coupling the anti-inflammatory and reparative readouts.¹²

GHK contributes to the same theme from a different direction: it has been proposed as a modulator of skin inflammation and is reported to shift gene-expression patterns associated with defence against oxidative stress.² Taken together, the anti-inflammatory literature for KLOW's components is real but model-specific — predominantly rodent gastrointestinal inflammation for KPV and cell/skin systems for GHK, not a generalisable claim.

Component-by-component evidence at a glance

The table summarises the strongest reported signal for each component and the model system it came from. It is deliberately organised by peptide, because no row describes the KLOW blend itself.

Where the evidence stops

Three limits should temper any reading of the sections above. First, the blend has no direct literature: every mechanism cited here belongs to an isolated compound, and combining peptides can change pharmacokinetics, stability and net effect in ways that cannot be inferred from the parts. Second, the evidence is overwhelmingly preclinical — in vitro assays and rodent models — and several BPC-157 findings concentrate in a single research lineage, which lowers the weight independent replication would give them. Third, the regulatory status is unambiguous: as of 2026 none of GHK-Cu, BPC-157, TB-500 or KPV is an FDA-approved drug, and TB-500 and BPC-157 in particular are not authorised for human use. GHK appears in cosmetic products, but a cosmetic ingredient status is not a therapeutic authorisation.

For researchers, the practical implication is that KLOW is a tool for generating hypotheses in controlled models, not a validated intervention. Reproducibility depends heavily on material identity and purity, which is why analytical documentation matters more here than in better-standardised reagent classes.

Open research directions

The gaps define the agenda. Meaningful next steps include:

• Blend-level pharmacology. Controlled comparison of the four-peptide mixture against each isolated component, to test whether the combination is additive, synergistic, or simply redundant in angiogenesis assays.
• Receptor and target mapping. Direct identification of the receptors and signalling nodes each peptide engages, rather than inference from downstream readouts such as VEGF or nitric-oxide tone.
• Stability and exposure profiling. Characterisation of degradation, solubility and reconstitution behaviour, since short peptides vary widely in stability and this governs experimental reproducibility.
• Independent replication. Confirmation of the strongest rodent findings — particularly for BPC-157 — by laboratories outside the originating groups.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.